Growing Bacteria in Petri Dishes on agar gel.

Antimicrobial resistance

Accelerating innovation to stem the global threat of antimicrobial resistance

Growing Bacteria in Petri Dishes on agar gel.

Antimicrobial resistance

Accelerating innovation to stem the global threat of antimicrobial resistance

Growing Bacteria in Petri Dishes on agar gel.

Antimicrobial resistance

Accelerating innovation to stem the global threat of antimicrobial resistance

The future of infection management won't be built by science alone

Increasing antimicrobial resistance (AMR) is one of the defining healthcare challenges of our generation. According to the World Health Organisation, Bacterial AMR is already linked to more than 4.7 million deaths annually. Without urgent action, AMR could cause up to 39 million deaths between 2025 and 2050, and cost the global economy $7.7 trillion by 2035, disproportionately affecting low- and middle-income countries.

Innovation in MedTech sits at the heart of the solution. Breakthrough innovations are emerging across rapid diagnostics, bacteriophage therapies, microbiome medicines, biologics, vaccines and connected health technologies. Yet many struggle to move beyond promising research because development, validation, manufacturing and adoption remain major barriers.

CPI has state-of-the-art expertise and facilities to help innovators accelerate progress, reduce development risk and build the capabilities needed to bring the next generation of AMR solutions to market.

Moving antimicrobial resistance innovation beyond the lab

There's no shortage of promising innovation in AMR. Researchers are developing novel diagnostics, from rapid molecular tests, community-based testing or devices that harness AI-insights, to treatments such as microbiome therapies, bacteriophages, vaccines and novel biologics. These are capable of transforming how resistant infections are detected, prevented and treated. 

The remaining challenge is translating discovery into industrial reality, and many innovations fail because they can’t be validated, manufactured, scaled or adopted efficiently enough to create real-world impact.  

That's where CPI helps. 

We work with innovators to accelerate development, reduce technical risk and overcome scale-up barriers. By generating data, evidence and validation early, we help organisations make informed development and investment decisions, while building the manufacturing capability and partnerships needed to bring AMR innovations closer to patients.

A CPI scientist swabbing a petri dish.
A CPI scientist swabbing a petri dish.
A CPI scientist swabbing a petri dish.

Our capabilities

We innovate with organisations across pharma and MedTech, bringing together expertise in diagnostics, advanced therapeutics, connected health technologies, bioprocessing and manufacturing to support the development and scale-up of solutions to tackle AMR.  

We support:

  • Technical risk reduction. 

  • Technology validation. 

  • Prototype development. 

  • Assay development. 

  • Process optimisation. 

  • Scale-up strategy. 

  • Regulatory readiness. 

  • Evidence generation. 

Areas of expertise 

Diagnostics

Rapid testing, microfluidics, assay development and connected diagnostics.

Explore CPI's capabilities in diagnostics.

Diagnostics

Rapid testing, microfluidics, assay development and connected diagnostics.

Explore CPI's capabilities in diagnostics.

Advanced therapeutics

Phages, microbiome products, recombinant proteins, antibodies and vaccines.  

Explore CPI's biologics and therapeutics capabilities. 

Advanced therapeutics

Phages, microbiome products, recombinant proteins, antibodies and vaccines.  

Explore CPI's biologics and therapeutics capabilities. 

Connected health technologies

Wearables, sensors and data-driven infection management.  

Explore CPI's patient monitoring capabilities.

Connected health technologies

Wearables, sensors and data-driven infection management.  

Explore CPI's patient monitoring capabilities.

Manufacturing and scale-up

Supporting the development and scale-up of manufacturing processes for diagnostics, medical devices and advanced therapeutics. 

Explore CPI's medtech development and scale-up capabilities.

Manufacturing and scale-up

Supporting the development and scale-up of manufacturing processes for diagnostics, medical devices and advanced therapeutics. 

Explore CPI's medtech development and scale-up capabilities.

Bioprocess development and scale-up

Bioprocessing, formulation, purification, analytics and GMP readiness. 

Explore CPI's bioprocess scale-up capabilities.

Bioprocess development and scale-up

Bioprocessing, formulation, purification, analytics and GMP readiness. 

Explore CPI's bioprocess scale-up capabilities.

Accelerate your AMR innovation with CPI

If you’re developing a new diagnostic, antimicrobial therapy or infection management technology, CPI can help you overcome technical challenges, reduce development risk and progress towards scalable manufacturing and commercialisation. 

Contents

Share

Share

Get in touch with us

Let’s explore how CPI can help bring your innovation to market faster.

A headshot of Hoda Kardooni.

Hoda Kardooni

Business Development Manager

Get in touch with us

Let’s explore how CPI can help bring your innovation to market faster.

A headshot of Hoda Kardooni.

Hoda Kardooni

Business Development Manager

Get in touch with us

Let’s explore how CPI can help bring your innovation to market faster.

A headshot of Hoda Kardooni.

Hoda Kardooni

Business Development Manager